ARTICLE | Emerging Company Profile
Adrestia’s synthetic rescue approach to genetic diseases
Cambridge spinout and GSK partner leveraging founder Steve Jackson’s DNA damage response expertise, outside of cancer
May 15, 2023 7:26 PM UTC
Adrestia believes the DNA damage response pathway its founder Steve Jackson put on the map for cancer synthetic lethality could also be a deep source of targets that induce “synthetic rescue”: inhibition of one biological signal to overcome dysfunction in another.
“You could drug synthetic rescue targets to rebalance a large range of genetic diseases,” Jackson told BioCentury. ...